From Intel to Samsung, global chipmakers are celebrating the beginning of the end of a semiconductor supply glut, but the outlook for demand from customers outside the artificial intelligence (AI) industry remains gloomy.

(Reuters) -AbbVie on Thursday trimmed its 2023 view for declining sales of its flagship arthritis drug Humira despite new competition, as favorable positions on insurance drug coverage lists helped it continue to reach U.S. patients.

Spanish bank BBVA on Friday said its second quarter net profit rose 24% from the same period in 2022 thanks to higher lending income in Mexico, its main market, and in Spain.

Oregon Senator Ron Wyden has asked the Federal Trade Commission, the Cybersecurity and Infrastructure Security Agency and the Department of Justice to 'take action' against Microsoft following a China-linked hack that reportedly resulted in the theft of thousands of government emails from top U.S. officials.

A look at the day ahead in European and global markets from Vidya Ranganathan

(Reuters) -AbbVie on Thursday raised its annual profit forecast after beating analysts' estimates for second-quarter earnings on a lower-than-expected fall in sales of blockbuster arthritis drug Humira and strong sales of newer treatments.